Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study
Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study
Ming Jiang, Lihua Qiu, Meifang Zheng, Qiantao Jia et al.
Citations
1 citations
Journal
EClinicalMedicine
Topics
Lymphoma Diagnosis and Treatment
Field-Weighted Citation Impact (FWCI)
1.47
article
Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study
Qingdao University (CN), Hebei Medical University (CN), Tongji University (CN), Union Hospital (HK), Sun Yat-sen University (CN), Peking University (CN), Nankai University (CN), Sichuan University (CN), Zhengzhou University (CN), West China Hospital of Sichuan University (CN), Fudan University Shanghai Cancer Center (CN), Jiangxi Provincial Cancer Hospital (CN), Linyi People's Hospital (CN), Jilin Province Tumor Hospital (CN), Fourth Hospital of Hebei Medical University (CN), Affiliated Hospital of Qingdao University (CN), Henan Provincial People's Hospital (CN), Peking University Third Hospital (CN), Henan Cancer Hospital (CN), Sun Yat-sen University Cancer Center (CN), Tongji Hospital (CN), Hubei Cancer Hospital (CN), Huazhong University of Science and Technology (CN), China Medical University (CN)